Form 8-K - Current report:
SEC Accession No. 0001645666-25-000001
Filing Date
2025-01-10
Accepted
2025-01-10 09:01:31
Documents
14
Period of Report
2025-01-10
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20250110.htm   iXBRL 8-K 25512
  Complete submission text file 0001645666-25-000001.txt   196948

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20250110.xsd EX-101.SCH 2658
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kzr-20250110_def.xml EX-101.DEF 16465
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20250110_lab.xml EX-101.LAB 29461
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20250110_pre.xml EX-101.PRE 17263
16 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20250110_htm.xml XML 4181
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 25520698
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)